Interleukin-4- and -13-induced hypercontractility of human intestinal muscle cells-implication for motility changes in Crohn's disease.
Crohn's disease is an idiopathic inflammatory condition. However, little is known about the changes that occur in the muscularis externa, despite the fact that this tissue contributes to motility changes and stricture formation. We characterized immune activity in the muscularis externa from intestinal segments of Crohn's disease patients and evaluated the role of IL-4 and -13 as well as signal transducer and activator of transcription (STAT)6 in the contractility of the cultured human intestinal smooth muscle cells. CD3+ve cells (P < 0.01) and IL-4 protein (P < 0.01) were significantly increased in the muscularis externa of Crohn's disease patients compared with noninflamed controls. Preincubation of human cultured smooth muscle cells with IL-4 (P < 0.001) or IL-13 (P < 0.05) significantly enhanced carbachol-induced contraction, and this was significantly inhibited by the STAT6 inhibitor leflunomide (P < 0.0001). A similar profile was observed in muscle cells isolated from Crohn's disease patients. Both IL-4 and IL-13 increased specific STAT6-DNA binding in control cells, and this was inhibited by anti-STAT6 Ab (P < 0.05) or leflunomide (P < 0.05). IL-4 and IL-13 mediate the hypercontractility of intestinal muscle via a STAT6 pathway at the level of the smooth muscle cell. The STAT6 pathway may contribute to the hypercontractility of intestinal muscle in Crohn's disease.
Akiho
Hirotada
H
Dept. of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu Univ., 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Lovato
Paola
P
Deng
Yikang
Y
Ceponis
Peter J M
PJ
Blennerhassett
Patricia
P
Collins
Stephen M
SM
D000328:Adult; D017252:CD3 Complex / Q000378:metabolism; D002217:Carbachol / Q000494:pharmacology; D016022:Case-Control Studies; D002478:Cells, Cultured; D003424:Crohn Disease / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D004247:DNA / Q000378:metabolism; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D018793:Interleukin-13 / Q000378:metabolism* / Q000494:pharmacology; D015847:Interleukin-4 / Q000378:metabolism* / Q000494:pharmacology; D007422:Intestines / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D032389:Myocytes, Smooth Muscle / Q000187:drug effects; D050800:STAT6 Transcription Factor; D014018:Tissue Distribution; D015534:Trans-Activators / Q000378:metabolism* / Q000502:physiology*
D017252:CD3 Complex; D018793:Interleukin-13; D050800:STAT6 Transcription Factor; C494101:STAT6 protein, human; D015534:Trans-Activators; D015847:Interleukin-4; D007371:Interferon-gamma; D002217:Carbachol; D004247:DNA